New hope for advanced cancers: experimental drug ACR-2316 enters first human trial

NCT ID NCT06667141

Recruiting now Disease control Sponsor: Acrivon Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 prior treatments and are still in fairly good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ACR-2316
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors who have limited other choices.
What could go wrong: This is a very early Phase 1 trial, so the drug may not be safe or effective. It is tested in a small group, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary sensory and autonomic neuropathy neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPECIFIC ADVANCED SOLID TUMORS

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
Denver Health One
RECRUITING

Denver, Colorado, 80218, United States
Florida Cancer Specialist
RECRUITING

Sarasota, Florida, 34232, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92663, United States
HonorHealth Research Institute
RECRUITING

Phoenix, Arizona, 85016, United States
Montefiore Medical Centre
RECRUITING

The Bronx, New York, 10461, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Next Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Precision NextGen Oncology & Research Center
RECRUITING

Beverly Hills, California, 90212, United States
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14203, United States
Tennessee Oncology
RECRUITING

Franklin, Tennessee, 37067, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77054, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.